Clinical studies reported a correlation between PKM2 expression and the prediction of chemosensitivity to epirubicin and 5-flurouracil (5-FU) based on the immunohistochemical analysis done in 296 patients diagnosed with invasive BC [126]. Here, PKM is linked to breast cancer.